Clinical Study
Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study
Table 1
Exclusion and inclusion criteria.
| | Exclusion criteria |
| | Retinopathy other than AMD | | Uncontrolled glaucoma (IOP ≥ 25 mmHg) | | NVG | | Active inflammation and/or infection in the study eye | | History of vitrectomy at any time | | Cataract surgery within the previous 3 months | | Ongoing therapy with other systemic or intravitreal steroids | | Other previous treatment for wet-AMD |
| | Retreatment criteria | | BCVA loss ≥5 ETDRS letters | | Recurrence or persistence of any fluid in the macula on SD-OCT | | A 10% increase in CSFT in comparison with the previous value | | New macular hemorrhages | | New area of classic CNV | | Development of new retinal PED or increase in size of an already existing PED |
|
|
AMD: age-related macular degeneration; IOP: intraocular pressure; NVG: neovascular glaucoma; BCVA: best corrected visual acuity; ETDRS: early treatment diabetic retinopathy study; SD-OCT: spectral domain optical coherence tomography; CSFT: central subfield foveal thickness; CNV: choroidal neovascularization; PED: pigment epithelium detachment.
|
